SCHEMBL797147

SCHEMBL797147

c1ccc(SCC2CC2)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.54
EHMT2 Q96KQ7 1/20 0.48
EHMT1 Q9H9B1 1/20 0.48
APOBEC3G Q9HC16 1/20 0.48
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 4/20 0.48
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.42
MEN1 O00255 2/20 0.42
PKM P14618 1/20 0.42
LMNA P02545 1/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 2/20 0.41
TSHR P16473 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9666178 0.90 CRBN (0.49) CRBNEHMT2EHMT1APOBEC3GALDH1A1
Hydrochloric Acid SCHEMBL4465656 0.87 CRBN (0.50) CRBNEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL5545416 0.85 CRBN (0.46) CRBNEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL9665181 0.85 CRBN (0.48) CRBNEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL9023817 0.83 CRBN (0.47) CRBNEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL9663523 0.81 CRBN (0.45) CRBNEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL4475396 0.81 POLB (0.54) CRBNALDH1A1KMT2ANPC1RAB9A
SCHEMBL27550957 0.78 CRBN (0.43) CRBNALDH1A1KMT2APOLBLMNA
Hydrochloric Acid SCHEMBL4478098 0.78 CRBN (0.46) CRBNEHMT2EHMT1APOBEC3GALDH1A1
SCHEMBL4151711 0.75 ALDH1A1 (0.50) CRBNALDH1A1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473429-A ROR gamma modulators 领先制药控股公司 2018-08-31 CN disclosed
CN-106164068-A Isoindolinone compounds as the GPR119 regulator for the treatment of diabetes, obesity, dyslipidemia and associated conditions 赛诺菲 2016-11-23 CN disclosed
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 US disclosed
EP-2616465-A1 TRIAZINE-OXADIAZOLES Novartis AG (CH) 2013-07-24 EP disclosed
WO-2012035023-A1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2012-03-22 WO disclosed
EP-0289002-A2 Novel cephalosporin compounds and antibacterial agents MEIJI SEIKA KAISHA LTD. (JP) 1988-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025057-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 CRBN 2002/4885EHMT2 3822/4885EHMT1 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.